What does the evidence say about Propolis Immune Function Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Propolis Immune Function Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Molecular epidemiological studies have identified approximately 20 species and genotypes associated with human infections, among whichandare the most frequently encountered in clinical settings (). [Xu Chang (2025); evidence level 4] - The findings identifiedas one of the four leading pathogens associated with moderate to severe diarrhea in children under 2 years of age (). [Xu Chang (2025); evidence level 4] - However, parasitic infections often lead to characteristic dysbiosis, marked by an increased abundance of Proteobacteria and a decreased abundance of Bacteroidetes (,). [Xu Chang (2025); evidence level 4] - parvum 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 , as a significant protozoan pathogen within the phylum Apicomplexa, is an opportunistic intestinal parasite of considerable public health importance. [Xu Chang (2025); evidence level 4] - With aging, the immune system exhibits less effective innate and adaptive immune responses [,,], leading to increased susceptibility to immunity related diseases []. [Pu Lingling (2024); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.